Young and the Invested on MSN

Low profile, high profit: High-earning roles for introverts that prize deep work over small talk

These are the best high-paying jobs for introverts.

How acupoints being sensitized and play for diseases diagnosis and treatment

Acupoints have long been viewed as fixed locations for therapeutic stimulation, yet emerging evidence suggests they are dynamic biological sites that change with disease states. This review ...

56th Best Workplace in Canada for 2026

Building a Culture That Earns Recognition: 56th Best Workplace in Canada for 2026 Toronto, Canada - April 3, 2026 / ...

Free software lets laptops simulate how aging evolves under selection

Why do some species live for only weeks while others survive for centuries? Researchers at the Leibniz Institute on ...

Four Florida Universities Take Top Honors in Florida Innovation Challenge Sponsored by the Orlando Magic

Miami Dade College received $9,000 in cash prizes of $50,000 total awarded to seven of the largest public colleges and ...
PCMag on MSN

Vibe coding 101: How to build apps and more with AI

Have an app you've always wanted to build? A humdrum task to automate? AI tools make it easier than ever, but they can be as ...
MarketWatch

Additional Phase 2 Data of AL-S Pharma's Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

The MarketWatch News Department was not involved in the creation of this content. Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an ...
Times Argus

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
Business Wire

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis ...
Yahoo Finance

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

Preparations underway to advance AP-101 into confirmatory Phase 3 clinical trial with initiation aimed for late 2026 ZURICH, March 19, 2026--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage ...